Skip to main content

Table 2 Performance features of five-marker stratification model

From: A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer

  

Prediction

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

Balanced accuracy (%)

Overall accuracy (%)

Overall AUC

Non-BC

LMR-NMIBC

HR-NMIBC + MIBC

Cohort 1 (model development)

Reference pathology

Non-BC

63

4

9

87.8

82.9

88.6

81.8

85.4

78.0

0.881

LMR-NMIBC

5

12

9

46.2

93.9

54.5

91.7

70.0

HR-NMIBC + MIBC

9

6

74

83.1

82.4

80.4

84.8

82.7

Cohort 2 (validation)

Reference pathology

Non-BC

34

3

2

91.1

87.2

91.1

87.2

89.1

82.1

0.889

LMR-NMIBC

3

6

5

42.9

93.8

54.5

90.5

68.3

HR-NMIBC + MIBC

2

2

38

90.5

86.8

84.4

92.0

88.6

  1. HR-NMIBC high-risk NMIBC, LMR-NMIBC low–intermediate-risk NMIBC, MIBC muscle invasive bladder cancer